Denali Therapeutics (Denali Therapeutics) Revenue per Share : $2.35 (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Denali Therapeutics Revenue per Share?

Denali Therapeutics's revenue per share for the three months ended in Dec. 2023 was $0.00. Denali Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.35.

Warning Sign:

Denali Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Denali Therapeutics was 178.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -6.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Denali Therapeutics's Revenue per Share or its related term are showing as below:

DNLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -34 Med: -6.9 Max: 45.8
Current: -6.9

During the past 9 years, Denali Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 45.80% per year. The lowest was -34.00% per year. And the median was -6.90% per year.

DNLI's 3-Year Revenue Growth Rate is ranked worse than
68.05% of 770 companies
in the Biotechnology industry
Industry Median: 5.4 vs DNLI: -6.90

Denali Therapeutics Revenue per Share Historical Data

The historical data trend for Denali Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Revenue per Share Chart

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

0.28

2.98

0.40

0.86

2.41

Denali Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue per Share	Get a 7-Day Free Trial															0.08	0.26	2.09	0.01	-

Competitive Comparison of Denali Therapeutics's Revenue per Share

For the Biotechnology subindustry, Denali Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Denali Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's PS Ratio falls into.

Denali Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Denali Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	330.531	/	137.371
	=	2.41

Denali Therapeutics's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )	=	Revenue (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	0	/	138.255
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.35

Denali Therapeutics (NAS:DNLI) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Denali Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (Denali Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

4DN:Germany

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Executives

Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho	officer: Chief Medical Officer	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts	director, officer: President and CEO	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes	officer: CFO and Treasurer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth	officer: COO and Secretary	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne	director	1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris	director	60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton	10 percent owner	201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631